PURPOSE: Numerous dietary factors elevate serum levels of insulin and insulin-like growth factor I (IGF-I), both potent prostate cancer mitogens. We tested whether varying dietary carbohydrate and fat, without energy restriction relative to comparison diets, would slow tumor growth and reduce serum insulin, IGF-I, and other molecular mediators of prostate cancer in a xenograft model. EXPERIMENTAL DESIGN: Individually caged male severe combined immunodeficient mice (n = 130) were randomly assigned to one of three diets (described as percent total calories): very high-fat/no-carbohydrate ketogenic diet (NCKD: 83% fat, 0% carbohydrate, 17% protein), low-fat/high-carbohydrate diet (LFD: 12% fat, 71% carbohydrate, 17% protein), or high-fat/moderate-carbohydrate diet (MCD: 40% fat, 43% carbohydrate, 17% protein). Mice were fed to maintain similar average body weights among groups. Following a preliminary feeding period, mice were injected with 1 x 10(6) LNCaP cells (day 0) and sacrificed when tumors were >or=1,000 mm(3). RESULTS: Two days before tumor injection, median NCKD body weight was 2.4 g (10%) and 2.1 g (8%) greater than the LFD and MCD groups, respectively (P < 0.0001). Diet was significantly associated with overall survival (log-rank P = 0.004). Relative to MCD, survival was significantly prolonged for the LFD (hazard ratio, 0.49; 95% confidence interval, 0.29-0.79; P = 0.004) and NCKD groups (hazard ratio, 0.59; 95% confidence interval, 0.37-0.93; P = 0.02). Median serum insulin, IGF-I, IGF-I/IGF binding protein-1 ratio, and IGF-I/IGF binding protein-3 ratio were significantly reduced in NCKD relative to MCD mice. Phospho-AKT/total AKT ratio and pathways associated with antiapoptosis, inflammation, insulin resistance, and obesity were also significantly reduced in NCKD relative to MCD tumors. CONCLUSIONS: These results support further preclinical exploration of carbohydrate restriction in prostate cancer and possibly warrant pilot or feasibility testing in humans.
PURPOSE: Numerous dietary factors elevate serum levels of insulin and insulin-like growth factor I (IGF-I), both potent prostate cancer mitogens. We tested whether varying dietary carbohydrate and fat, without energy restriction relative to comparison diets, would slow tumor growth and reduce serum insulin, IGF-I, and other molecular mediators of prostate cancer in a xenograft model. EXPERIMENTAL DESIGN: Individually caged male severe combined immunodeficientmice (n = 130) were randomly assigned to one of three diets (described as percent total calories): very high-fat/no-carbohydrate ketogenic diet (NCKD: 83% fat, 0% carbohydrate, 17% protein), low-fat/high-carbohydrate diet (LFD: 12% fat, 71% carbohydrate, 17% protein), or high-fat/moderate-carbohydrate diet (MCD: 40% fat, 43% carbohydrate, 17% protein). Mice were fed to maintain similar average body weights among groups. Following a preliminary feeding period, mice were injected with 1 x 10(6) LNCaP cells (day 0) and sacrificed when tumors were >or=1,000 mm(3). RESULTS: Two days before tumor injection, median NCKD body weight was 2.4 g (10%) and 2.1 g (8%) greater than the LFD and MCD groups, respectively (P < 0.0001). Diet was significantly associated with overall survival (log-rank P = 0.004). Relative to MCD, survival was significantly prolonged for the LFD (hazard ratio, 0.49; 95% confidence interval, 0.29-0.79; P = 0.004) and NCKD groups (hazard ratio, 0.59; 95% confidence interval, 0.37-0.93; P = 0.02). Median serum insulin, IGF-I, IGF-I/IGF binding protein-1 ratio, and IGF-I/IGF binding protein-3 ratio were significantly reduced in NCKD relative to MCDmice. Phospho-AKT/total AKT ratio and pathways associated with antiapoptosis, inflammation, insulin resistance, and obesity were also significantly reduced in NCKD relative to MCD tumors. CONCLUSIONS: These results support further preclinical exploration of carbohydrate restriction in prostate cancer and possibly warrant pilot or feasibility testing in humans.
Authors: Tung H Ngo; R James Barnard; Todd Anton; Chris Tran; David Elashoff; David Heber; Stephen J Freedland; William J Aronson Journal: Cancer Res Date: 2004-02-15 Impact factor: 12.701
Authors: Tung H Ngo; R James Barnard; Pinchas Cohen; Stephen Freedland; Chris Tran; Frank deGregorio; Yahya I Elshimali; David Heber; William J Aronson Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Gary D Foster; Holly R Wyatt; James O Hill; Brian G McGuckin; Carrie Brill; B Selma Mohammed; Philippe O Szapary; Daniel J Rader; Joel S Edman; Samuel Klein Journal: N Engl J Med Date: 2003-05-22 Impact factor: 91.245
Authors: Thomas W-M Boileau; Zhiming Liao; Sunny Kim; Stanley Lemeshow; John W Erdman; Steven K Clinton Journal: J Natl Cancer Inst Date: 2003-11-05 Impact factor: 13.506
Authors: Jessica C Lloyd; Jodi A Antonelli; Tameika E Phillips; Elizabeth M Masko; Jean-Alfred Thomas; Susan H M Poulton; Michael Pollak; Michael Pollack; Stephen J Freedland Journal: J Urol Date: 2010-02-20 Impact factor: 7.450
Authors: Cristian P Moiola; Paola De Luca; Florencia Zalazar; Javier Cotignola; Santiago A Rodríguez-Seguí; Kevin Gardner; Roberto Meiss; Pablo Vallecorsa; Omar Pignataro; Osvaldo Mazza; Elba S Vazquez; Adriana De Siervi Journal: Clin Cancer Res Date: 2014-05-19 Impact factor: 12.531
Authors: John V Heymach; Terry J Shackleford; Hai T Tran; Suk-Young Yoo; Kim-Anh Do; Melanie Wergin; Pierre Saintigny; Robin T Vollmer; Thomas J Polascik; Denise C Snyder; Mack T Ruffin; Shaoyu Yan; Mark Dewhirst; Ajaikumar B Kunnumakkara; Bharat B Aggarwal; Wendy Demark-Wahnefried Journal: Cancer Prev Res (Phila) Date: 2011-07-15
Authors: Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2012-10-04 Impact factor: 4.104